Modification to the A11 HERV-E TCR and T cell product to improve the therapeutic efficacy for ccRCC patients.

The contract involves a modification to the A11 HERV-E TCR and T cell product aimed at enhancing its therapeutic efficacy for patients with clear cell renal cell carcinoma (ccRCC). It is issued by the National Institutes of Health under the Department of Health and Human Services and categorized under the healthcare services industry. The solicitation, identified by the number 75N98026Q00392, was posted on May 19, 2026, with a response deadline set for June 3, 2026. This is a presolicitation notice, specifically a Notice of Intent to Sole Source, indicating that the contract may be awarded without a competitive bidding process. The place of performance for this contract is Bethesda, Maryland, where the issuing office is located. There is no set-aside used for this contract, suggesting it is open without designated preferences for small or disadvantaged businesses. The primary contact for inquiries or submissions is Michael L. Falzone, and all communications are directed through the specified NIH email address. This procurement is focused on advancing a targeted therapeutic product within the biomedical research and development sector.